+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Europe Liquid Biopsy Market to 2027 - Regional Analysis and Forecasts by Product & Services; Sample; Application; End User; and, Country

  • ID: 5138194
  • Report
  • August 2020
  • Region: Europe
  • 143 pages
  • The Insight Partners
UP TO OFF
until Jan 15th 2021

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Exosome Diagnostics
  • F. Hoffmann-La Roche Ltd.
  • Inivata Ltd.
  • LungLife AI, Inc.
  • MDxHealth
  • MORE

Europe, the liquid biopsy market, is anticipated to reach US$ 2,251.12 Mn in 2027 from US$ 1,097.82 Mn in 2019. The market is projected to grow with a CAGR of 9.5% from 2019-2027.

The liquid biopsy market is growing primarily due to government and global health organizations initiatives. Restraining factors, such as low sensitivity of liquid biopsy, is likely to damage the growth of the market in the coming years. On the other hand, rising liquid biopsy due to growing application and advancements is expected to have a positive impact on the growth of the Europe liquid biopsy market in the coming years.

Liquid biopsy is a revolutionary technology that is opening up various perspectives. The technology consists of isolation and detection of circulating tumor cells, circulating tumor DNA and exosomes, which provides genomic information of the cancer patients. Liquid biopsy are used in cancer diagnosis in order to study response or resistance to given treatments.

The liquid biopsy test is conducted to detect cancer at an early stage. The test is performed either on a blood sample to identify cancer cells present in the in blood stream, or on the DNA extracted from tumor cells. The government for early detection of cancer takes various initiatives. For instance, the National Institutes of Health (NIH) started a new initiative called Pre-competitive Collaboration on Liquid Biopsy for Early Cancer Assessment. The purposes of this initiative are to establish a Public-Private Partnership Program for the development of new or validate existing technologies, methods, and assays for the capture and quantification of tumor-associated cells, RNA, DNA, or exosomes in body fluids of patients with an early-stage disease or those at high risk. This initiative emphasis early cancer detection, distinguishing between aggressive from non-aggressive cancers, and to differentiate benign disease from cancer.

The NCI's commitment of funds towards R&D of clinical advanced technology will encourage the investigators to expand their research for early detection and accelerate clinical adoption of these promising technologies.

European countries are also taking initiatives for early detection of cancer. For instance, the Innovative Medicines Initiative funded the CANCER-ID project, started on 1January 2015. It is a public-private partnership between the EU and the European pharmaceutical industry, which includes 38 partners from 13 European countries, along with groups from the US and a company in Singapore. These partners are brought together to develop and validate standardized operating procedures for liquid biopsies. Such increasing initiatives for liquid biopsy, it is likely to boost the growth of the global liquid biopsy market during the forecast period.

In 2019, the reagents & kits segment accounted for the largest market share in the Europe liquid biopsy market based on the product & services, and the similar segment is estimated to mark the highest CAGR in the market during the forecast period, owing to the availability of complete set of kits for liquid biopsy.

Moreover, the European Society for Medical Oncology (ESMO) is the leading professional organization for medical oncology, is continuing to help oncology professionals by helping them to deliver optimal care to their cancer patients in such situations. The impact of the COVID-19 pandemic on cancer patients is high in terms of anxiety, fear, and psychological distress. However, due to growing COVID-19, the supply of diagnostics kits and assays are delayed because of growing quarantine time and shutting down all business operations. Europe is facing the massive impact of an outbreak due to exponential growth of infections in the region. As per data published by public sources, till March 26, Europe had an estimated 250,000 number of infected patients in the region. The outbreak badly hits countries such as Italy, Spain, Germany, France, and the UK.

Some of the significant primary and secondary sources for liquid biopsy included in the report are Biotechnology and Biological Sciences Research Council (BBSRC), British Journal of Surgery (BJS), Cancer Center Amsterdam (CCA), International Diabetes Federation (IDF), an

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Exosome Diagnostics
  • F. Hoffmann-La Roche Ltd.
  • Inivata Ltd.
  • LungLife AI, Inc.
  • MDxHealth
  • MORE
1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Liquid Biopsy Market - By Product & Service
1.3.2 Europe Liquid Biopsy Market - By Sample
1.3.3 Europe Liquid Biopsy Market - By Circulating Biomarker
1.3.4 Europe Liquid Biopsy Market - By Application
1.3.5 Europe Liquid Biopsy Market - By End User
1.3.6 Europe Liquid Biopsy Market - By Country

2. Europe Liquid Biopsy Market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Liquid Biopsy Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Europe Liquid Biopsy Market - Europe PEST Analysis
4.3 Expert Opinion

5. Europe Liquid Biopsy - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Government and Global Health Organizations Initiatives
5.2 Key Restraints
5.2.1 Low Sensitivity of Liquid Biopsy
5.3 Key Market Opportunities
5.3.1 Rising Liquid Biopsy Due to Growing Application and Advancements
5.4 Future Trends
5.4.1 Consistent Launch of New Products
5.5 Impact Analysis

6. Liquid Biopsy Market - Europe Analysis
6.1 Europe Liquid Biopsy Market Revenue Forecasts and Analysis

7. Liquid Biopsy Market Analysis - By Product & Services
7.1 Overview
7.2 Liquid Biopsy Market Revenue Share, by Product& Service (2019 and 2027)
7.3 Equipment
7.3.1 Overview
7.4 Equipment: Liquid Biopsy Market - Revenue and Forecast to 2027 (US$ Million)
7.5 Reagents & Kits
7.5.1 Overview
7.5.2 Reagents & Kits: Liquid Biopsy Market - Revenue and Forecast to 2027 (US$ Million)
7.6 Services
7.6.1 Overview
7.6.2 Services: Liquid Biopsy Market - Revenue and Forecast to 2027 (US$ Million)

8. Liquid Biopsy Market Analysis - By Sample
8.1 Overview
8.2 Liquid Biopsy Market, by Sample, 2019 and 2027 (%)
8.3 Blood Based
8.3.1 Overview
8.3.2 Blood Based: Liquid Biopsy Market - Revenue and Forecast to 2027 (US$ Million)
8.4 Urine Based
8.4.1 Overview
8.4.2 Urine Based: Liquid Biopsy Market - Revenue and Forecast to 2027 (US$ Million)
8.5 Other Samples
8.5.1 Overview
8.6 Other Samples: Liquid Biopsy Market - Revenue and Forecast to 2027 (US$ Million)

9. Liquid Biopsy Market Analysis - By Circulating Biomarker
9.1 Overview
9.2 Liquid Biopsy Market, by Circulating Biomarker, 2019 and 2027 (%)
9.3 Circulating Tumor Cells (CTC)
9.3.1 Overview
9.3.2 Circulating Tumor Cell (CTC): Liquid Biopsy Market - Revenue and Forecast to 2027 (US$ Million)
9.4 Exosomes
9.4.1 Overview
9.4.2 Exosomes: Liquid Biopsy Market - Revenue and Forecast to 2027 (US$ Million)
9.5 Free Nucleic Acid
9.5.1 Overview
9.6 Free Nucleic Acid: Liquid Biopsy Market - Revenue and Forecast to 2027 (US$ Million)

10. Liquid Biopsy Market Analysis - By Application
10.1 Overview
10.2 Liquid Biopsy Market, by Application, 2019 and 2027 (%)
10.3 Non-invasive Prenatal Testing (NIPT)
10.3.1 Overview
10.3.2 Noninvasive prenatal testing (NIPT): Liquid Biopsy Market - Revenue and Forecast to 2027 (US$ Million)
10.4 Oncology
10.4.1 Overview
10.4.2 Oncology: Liquid Biopsy Market - Revenue and Forecast to 2027 (US$ Million)
10.5 Transplant Diagnostics
10.5.1 Overview
10.5.2 Transplant Diagnostics: Liquid Biopsy Market - Revenue and Forecast to 2027 (US$ Million)
10.6 Other Applications
10.6.1 Overview
10.7 Other applications: Liquid Biopsy Market - Revenue and Forecast to 2027 (US$ Million)

11. Liquid Biopsy Market Analysis - By End User
11.1 Overview
11.2 Liquid Biopsy Market, by End-User, 2019 and 2027 (%)
11.3 Academic & Research Institutes
11.3.1 Overview
11.3.2 Academic & Research Institutes: Liquid Biopsy Market - Revenue and Forecast to 2027 (US$ Million)
11.4 Hospitals
11.4.1 Overview
11.4.2 Hospitals: Liquid Biopsy Market - Revenue and Forecast to 2027 (US$ Million)
11.5 Reference Laboratories
11.5.1 Overview
11.6 Reference Laboratories: Liquid Biopsy Market - Revenue and Forecast to 2027 (US$ Million)
11.7 Other End Users
11.7.1 Overview
11.8 Other End Users: Liquid Biopsy Market - Revenue and Forecast to 2027 (US$ Million)

12. Liquid Biopsy Market Revenue and Forecasts To 2027 - Geographical Analysis
12.1 Europe Liquid Biopsy Market Revenue and Forecasts To 2027
12.1.1 Overview
12.1.2 Europe: Liquid Biopsy Market - Revenue and Forecast to 2027 (USD Million)
12.1.3 Europe: Liquid Biopsy Market, by Product & Service, 2018-2027 (USD Million)
12.1.4 Europe: Liquid Biopsy Market, by Sample, 2018-2027 (USD Million)
12.1.5 Europe: Liquid Biopsy Market, by Circulating Biomarker, 2018-2027 (USD Million)
12.1.6 Europe: Liquid Biopsy Market, by Application, 2018-2027 (USD Million)
12.1.7 Europe: Liquid Biopsy Market, by End User, 2018-2027 (USD Million)
12.1.8 Europe: Liquid Biopsy Market, by Country, 2018 & 2027 (%)
12.1.9 Germany: Liquid Biopsy Market - Revenue and Forecast to 2027 (USD Million)
12.1.9.1 Germany: Liquid Biopsy Market - Revenue and Forecast to 2027 (USD Million)
12.1.9.2 Germany: Liquid Biopsy Market, by Product & Service, 2018-2027 (USD Million)
12.1.9.3 Germany: Liquid Biopsy Market, by Sample, 2018-2027 (USD Million)
12.1.9.4 Germany: Liquid Biopsy Market, by Circulating Biomarker, 2018-2027 (USD Million)
12.1.9.5 Germany: Liquid Biopsy Market, by Application, 2018-2027 (USD Million)
12.1.9.6 Germany: Liquid Biopsy Market, by End User, 2018-2027 (USD Million)
12.1.10 UK: Liquid Biopsy Market - Revenue and Forecast to 2027 (USD Million)
12.1.10.1 UK: Liquid Biopsy Market - Revenue and Forecast to 2027 (USD Million)
12.1.10.2 UK: Liquid Biopsy Market, by Product & Service, 2018-2027 (USD Million)
12.1.10.3 UK: Liquid Biopsy Market, by Sample, 2018-2027 (USD Million)
12.1.10.4 UK: Liquid Biopsy Market, by Circulating Biomarker, 2018-2027 (USD Million)
12.1.10.5 UK: Liquid Biopsy Market, by Application, 2018-2027 (USD Million)
12.1.10.6 UK: Liquid Biopsy Market, by End User, 2018-2027 (USD Million)
12.1.11 France: Liquid Biopsy Market - Revenue and Forecast to 2027 (USD Million)
12.1.11.1 France: Liquid Biopsy Market - Revenue and Forecast to 2027 (USD Million)
12.1.11.2 France: Liquid Biopsy Market, by Product & Service, 2018-2027 (USD Million)
12.1.11.3 France: Liquid Biopsy Market, by Sample, 2018-2027 (USD Million)
12.1.11.4 France: Liquid Biopsy Market, by Circulating Biomarker, 2018-2027 (USD Million)
12.1.11.5 France: Liquid Biopsy Market, by Application, 2018-2027 (USD Million)
12.1.11.6 France: Liquid Biopsy Market, by End User, 2018-2027 (USD Million)
12.1.12 Spain: Liquid Biopsy Market - Revenue and Forecast to 2027 (USD Million)
12.1.12.1 Spain: Liquid Biopsy Market - Revenue and Forecast to 2027 (USD Million)
12.1.12.2 Spain: Liquid Biopsy Market, by Product & Service, 2018-2027 (USD Million)
12.1.12.3 Spain: Liquid Biopsy Market, by Sample, 2018-2027 (USD Million)
12.1.12.4 Spain: Liquid Biopsy Market, by Circulating Biomarker, 2018-2027 (USD Million)
12.1.12.5 Spain: Liquid Biopsy Market, by Application, 2018-2027 (USD Million)
12.1.12.6 Spain: Liquid Biopsy Market, by End User, 2018-2027 (USD Million)
12.1.13 Italy: Liquid Biopsy Market - Revenue and Forecast to 2027 (USD Million)
12.1.13.1 Italy: Liquid Biopsy Market - Revenue and Forecast to 2027 (USD Million)
12.1.13.2 Italy: Liquid Biopsy Market, by Product & Service, 2018-2027 (USD Million)
12.1.13.3 Italy: Liquid Biopsy Market, by Sample, 2018-2027 (USD Million)
12.1.13.4 Italy: Liquid Biopsy Market, by Circulating Biomarker, 2018-2027 (USD Million)
12.1.13.5 Italy: Liquid Biopsy Market, by Application, 2018-2027 (USD Million)
12.1.13.6 Italy: Liquid Biopsy Market, by End User, 2018-2027 (USD Million)

13. Impact of COVID-19 Pandemic on Global Liquid Biopsy Market
13.1 Europe: Impact Assessment of COVID-19 Pandemic

14. Company Profiles
14.1 F. Hoffmann-la Roche ltd
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Inivata Ltd
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 LungLife AI, Inc.
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Exosome Diagnostics
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 MDxHealth
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments

15. Appendix
15.1 About the Publisher
15.2 Glossary of Terms
Note: Product cover images may vary from those shown
  • F. Hoffmann-La Roche Ltd.
  • Inivata Ltd.
  • LungLife AI, Inc.
  • Exosome Diagnostics
  • MDxHealth
Note: Product cover images may vary from those shown
Adroll
adroll